In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 vaccine Spikevax in children aged six months through 11 years who are at ...

Dupixent (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of adult patients with bullous pemphigoid. Dupixent Gains Approval for Bullous Pemphigoid mNexspike (COVID-19 vaccine ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The new vaccine (mNexspike [COVID-19 Vaccine, mRNA]) represents a significant step forward in the development of next-generation coronavirus vaccines, the Associated Press reported.

Wall Street surged as the S&P 500 reclaimed 6,000, fueled by a strong jobs report. Discover market movers like Tesla, Moderna, and Procter & Gamble.

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a label narrower than initially targeted. The vaccine will be marketed under ...

Moderna’s new COVID-19 vaccine, named mNexspike, is a fifth of the dose of its current COVID-19 vaccine, Spikevax. It is considered a step toward next-generation coronavirus vaccines.